Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M48,038Revenue $M5,770Net Margin (%)6.2Z-Score1.8
Enterprise Value $M63,615EPS $-2.7Operating Margin %20.2F-Score7
P/E(ttm))126Cash Flow Per Share $4.9Pre-tax Margin (%)5.3Higher ROA y-yY
Price/Book12.010-y EBITDA Growth Rate %3.7Quick Ratio1.1Cash flow > EarningsY
Price/Sales7.85-y EBITDA Growth Rate %41.3Current Ratio1.4Lower Leverage y-yY
Price/Cash Flow11.8y-y EBITDA Growth Rate %164ROA % (ttm)1.8Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)9.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M336ROI % (ttm)-4.0Gross Margin Increase y-yY

Gurus Latest Trades with VRX

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRXGlenn Greenberg 2014-09-30 Add2.6%$106.73 - $130.26
($118.9)
$ 159.9734%Add 8.86%6,586,582
VRXLou Simpson 2014-09-30 Add1.01%$106.73 - $130.26
($118.9)
$ 159.9734%Add 12.4%1,815,916
VRXWallace Weitz 2014-09-30 Add0.54%$106.73 - $130.26
($118.9)
$ 159.9734%Add 9.05%1,691,525
VRXSteve Mandel 2014-09-30 Add0.46%$106.73 - $130.26
($118.9)
$ 159.9734%Add 8.89%10,985,940
VRXChris Davis 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 159.9734%Add 11.91%3,529,237
VRXGeorge Soros 2014-09-30 Add0.15%$106.73 - $130.26
($118.9)
$ 159.9734%Add 32.73%626,748
VRXRuane Cunniff 2014-09-30 Add0.14%$106.73 - $130.26
($118.9)
$ 159.9734%Add 0.57%34,494,015
VRXAndreas Halvorsen 2014-09-30 Reduce-1.02%$106.73 - $130.26
($118.9)
$ 159.9734%Reduce -15.75%9,967,690
VRXLee Ainslie 2014-09-30 Reduce-0.18%$106.73 - $130.26
($118.9)
$ 159.9734%Reduce -3.7%2,527,896
VRXJoel Greenblatt 2014-09-30 Sold Out -0.01%$106.73 - $130.26
($118.9)
$ 159.9734%Sold Out0
VRXGlenn Greenberg 2014-06-30 Add2.33%$116.99 - $138.13
($127.6)
$ 159.9725%Add 8.19%6,050,442
VRXAndreas Halvorsen 2014-06-30 Add1.39%$116.99 - $138.13
($127.6)
$ 159.9725%Add 27.27%11,830,932
VRXSteve Mandel 2014-06-30 Add0.64%$116.99 - $138.13
($127.6)
$ 159.9725%Add 14.44%10,089,450
VRXLee Ainslie 2014-06-30 Add0.37%$116.99 - $138.13
($127.6)
$ 159.9725%Add 8.39%2,625,014
VRXGeorge Soros 2014-06-30 Add0.29%$116.99 - $138.13
($127.6)
$ 159.9725%Add 185.46%472,187
VRXChris Davis 2014-06-30 Add0.17%$116.99 - $138.13
($127.6)
$ 159.9725%Add 16.03%3,153,748
VRXJoel Greenblatt 2014-06-30 Buy 0.01%$116.99 - $138.13
($127.6)
$ 159.9725%New holding, 6172 sh.6,172
VRXDaniel Loeb 2014-06-30 Sold Out -0.48%$116.99 - $138.13
($127.6)
$ 159.9725%Sold Out0
VRXJohn Paulson 2014-06-30 Reduce-0.32%$116.99 - $138.13
($127.6)
$ 159.9725%Reduce -49.97%500,300
VRXWallace Weitz 2014-06-30 Reduce-0.19%$116.99 - $138.13
($127.6)
$ 159.9725%Reduce -2.91%1,551,076
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
VRX George Soros 2014-09-30626,7480.190.61+32.73%
VRX Lou Simpson 2014-09-301,815,9160.549.2+12.4%
VRX Chris Davis 2014-09-303,529,2371.051.4+11.91%
VRX Wallace Weitz 2014-09-301,691,5250.56.5+9.05%
VRX Steve Mandel 2014-09-3010,985,9403.275.6+8.89%
VRX Glenn Greenberg 2014-09-306,586,5821.9632+8.86%
VRX John Paulson 2014-09-30520,7000.160.28+4.08%
VRX Ruane Cunniff 2014-09-3034,494,01510.2824+0.57%
VRX Jeff Ubben 2014-09-3018,923,8775.6416.6
VRX Private Capital 2014-09-30296,8710.094.6-1.19%
VRX Jean-Marie Eveillard 2014-09-301,010,8020.30.33-1.33%
VRX Lee Ainslie 2014-09-302,527,8960.754.8-3.7%
VRX Andreas Halvorsen 2014-09-309,967,6902.975.3-15.75%
VRX Joel Greenblatt 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


VRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Farmer Ronald HaroldDirector 2014-12-12Buy500$160.48-0.32view
UBBEN JEFFREY W 2014-12-10Buy250,000$140.0614.22view
Stevenson, Katharine BerghuisDirector 2014-12-03Buy1,500$145.739.77view
STEVENSON KATHARINE BERGHUISDirector 2014-12-03Buy1,500$145.739.77view
Farmer, RonDirector 2014-11-24Buy1,000$163.95-2.43view
Farmer Ronald HaroldDirector 2014-11-24Buy1,000$163.95-2.43view
UBBEN JEFFREY W 2014-11-24Buy210,000$142.2512.46view
Chai-Onn Robert RoswellEVP, Gen. Couns. & Corp. Secy. 2014-06-23Sell10,203$121.731.45view
Chai-Onn, Robert RoswellSenior Officer 2014-06-23Sell10,203$121.731.45view
Mirovsky, PavelSenior Officer 2014-06-02Sell10,000$131.2521.88view

Press Releases about VRX :

Quarterly/Annual Reports about VRX:

News about VRX:

Articles On GuruFocus.com
Weitz Value Fund Q4 2014 Commentary Jan 26 2015 
New Guru Jana Partners' Newest Stock Buys Jan 22 2015 
Analysts Make Bullish Ratings in Response to Valeant’s Increased 2015 Guidance Jan 12 2015 
Wallace Weitz Buys Discovery Communications, Sells Apple in Q3 Nov 14 2014 
Former Warren Buffett CIO Lou Simpson Buys Liberty Global, Valeant, U.S. Bancorp, Sells TE Connectiv Nov 14 2014 
Ackman’s Pershing Group Buys Stake in Zoetis Nov 13 2014 
Valeant Part XIII: channeling Jeff Skilling - or trying to reconstruct Valeant's balance sheet Oct 30 2014 
Wallace Weitz's Partners Value Fund Q3 2014 Commentary Oct 16 2014 
Ackman's Pershing Square Now Available To The Public Oct 13 2014 
Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 

More From Other Websites
After Allergan loss, is Valeant dumpster diving? Jan 31 2015
Valeant Pharmaceuticals International, Inc -- Moody's: Valeant's oncology foray credit positive but... Jan 30 2015
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive... Jan 30 2015
Valeant Agrees To Buy Dendreon's Provenge Jan 30 2015
The Daily Docket: Trump Taj Mahal Workers Protest Outside Icahn's Office Jan 30 2015
Valeant Hopes To Buy Cancer Drug From Dendreon For $296M Jan 30 2015
Activis CEO: Innovation vs. acquisition Jan 30 2015
Dendreon's Asset Rummage Sale Completes the Circle of Life Jan 30 2015
2:57 am Valeant Pharma: Dendreon (DNDN, DNDNQ) reaches agreement for Valeant to serve as 'Stalking... Jan 30 2015
Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment,... Jan 29 2015
Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment,... Jan 29 2015
Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment,... Jan 29 2015
Top Large-Cap Growth Stock Funds: Back On Their Feet Jan 28 2015
Large Medicals, Indian Stocks Rally To New Highs Jan 26 2015
Actavis Buys Auden Mckenzie, Now UK's Largest Generics Firm Jan 26 2015
IBD 50 Turns In Solid Week As Market Uptrend Resumes Jan 23 2015
New Guru Jana Partners' Newest Stock Buys Jan 22 2015
Valeant's Bausch + Lomb Imaging System Cleared by FDA - Analyst Blog Jan 21 2015
Hungry Actavis pauses to digest Allergan Jan 21 2015
Valeant chief Pearson admits 'miscalculation' in Allergan pursuit Jan 21 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK